Show simple item record

dc.contributor.authorMatsubara, Nobuaki
dc.contributor.authorFizazi, Karim
dc.contributor.authorHu, Peter
dc.contributor.authorFeyerabend, Susan
dc.contributor.authorChi, Kim N.
dc.contributor.authorBaciarello, Giulia
dc.contributor.authorÖZGÜROĞLU, MUSTAFA
dc.contributor.authorMundle, Suneel
dc.contributor.authorLeitz, Gerhard
dc.contributor.authorRicharz, Ute
dc.date.accessioned2022-07-04T14:51:34Z
dc.date.available2022-07-04T14:51:34Z
dc.identifier.citationBaciarello G., ÖZGÜROĞLU M., Mundle S., Leitz G., Richarz U., Hu P., Feyerabend S., Matsubara N., Chi K. N. , Fizazi K., "<p>Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study</p>", EUROPEAN JOURNAL OF CANCER, cilt.162, ss.56-64, 2022
dc.identifier.issn0959-8049
dc.identifier.othervv_1032021
dc.identifier.otherav_916d4fc3-0ffe-4ed8-8113-0e589ce16639
dc.identifier.urihttp://hdl.handle.net/20.500.12627/183753
dc.identifier.urihttps://doi.org/10.1016/j.ejca.2021.11.026
dc.description.abstractBackground: A post-hoc analysis of the phase-3 LATITUDE study assessed the impact of abiraterone acetate plus prednisone (AA+P) on overall survival (OS) and radiographic progression-free survival (rPFS) in men with metastatic castration-sensitive prostate cancer (mCSPC) and visceral metastases (VM).& nbsp;Methods: Newly diagnosed mCSPC patients were randomized (1:1) to AA+P and androgen deprivation therapy (ADT) or placebo+ADT. Patients with VM in liver or lungs with or without other soft tissue and bone metastases (based on CT/MRI) at baseline were analyzed, after 51.8 months' median follow-up. Co-primary endpoints, OS and rPFS, were analyzed.& nbsp;Results: Among 1199 patients enrolled, 228 (19%) had VM at baseline (114 each in AA+P and placebo groups), of which 53 (23.2%; AA+P = 29, Placebo = 24) had liver metastases and 117 (51.3%; AA+P = 60, Placebo = 57) had lung metastases. In patients with VM, treatment with AA+P versus placebo showed an improvement in OS (median 55.4 vs 33.0 months; HR = 0.582; 95%CI = 0.406-0.835;P = 0.0029) and rPFS (median 30.7 vs 18.3 months; HR = 0.527; 95%CI = 0.366-0.759;P = 0.0005), comparable to that of patients without VM. AA+P versus placebo in lung metastases patients was associated with greater improvement in OS (HR = 0.60; 95%CI = 0.35-1.04;P = 0.0678) than in liver metastases patients (HR = 0.82; 95%CI = 0.41-1.66;P = 0.5814). AA+P versus placebo showed improvement in rPFS in lung metastases patients (HR = 0.50; 95%CI = 0.29-0.89;P = 0.0157), but not in liver metastases patients (HR = 1.05; 95%CI = 0.53-2.09; P = 0.8970).& nbsp;Conclusion: AA+P treatment improved both rPFS and OS in men with mCSPC and visceral disease, especially those with lung metastases. Men with liver metastases had a poorer prognosis and their optimal treatment remains to be defined. (C)2021 The Authors. Published by Elsevier Ltd.& nbsp;
dc.language.isoeng
dc.subjectOnkoloji
dc.subjectOncology
dc.subjectHealth Sciences
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectSağlık Bilimleri
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.subjectTıp
dc.title<p>Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study</p>
dc.typeMakale
dc.relation.journalEUROPEAN JOURNAL OF CANCER
dc.contributor.departmentLeague of European Research Universities - LERU , ,
dc.identifier.volume162
dc.identifier.startpage56
dc.identifier.endpage64
dc.contributor.firstauthorID3431215


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record